Nuclear receptor (NR) superfamily is located in the transcriptional regulator class. Owing to their important role in controlling many physiological and pathological events, it has become the most important therapeutic targets in clinical trials. Although it is used successfully in many cases, allowing receptor-modulating drugs, owing to targeted therapy resistance, the mechanisms of NRs that work for generating new drugs are still up to date. Most successful target therapy for controlling the activity of the receptor was conducted based on the NR signaling pathway. In this review, estrogen receptor (ER) subtypes, ER domain structure and general features, ER molecular signaling mechanisms, ER degradation occurring with the ubiquitin–proteasome pathway, ER degradation triggered by basal and ligand, effect of ER concentration in response to estrogen, and ER alpha molecular background of the action of agonists and antagonists are explained in detail. The comprehensive information in this article is intended to provide a clearer understanding of the receptor function in the control of key points. We believe that it would be useful for future therapeutic approaches.
Corresponding Author: Okat Z.